2024
A Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy
Hofmeister C, Gupta V, Joseph N, Lonial S, Dhodapkar M, Nooka A, Kaufman J. A Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy. Blood 2024, 144: 4672. DOI: 10.1182/blood-2024-203485.Peer-Reviewed Original ResearchAL amyloidosisPlasma cell-directed therapyHigh-sensitivity troponin THematological complete remissionSevere cardiac involvementCell-directed therapiesPoor performance statusMonths of treatmentEnd-stage cardiomyopathyDaratumumab monotherapyComplete remissionCardiac involvementNT-proBNPPerformance statusAmyloid cardiomyopathyTherapeutic optionsSevere cardiomyopathyHeart transplantationStage 3bDirected therapyDiagnosed patientsEuropean trialsClinical consequencesTroponin TTargeted treatmentAplastic anemia in association with multiple myeloma: clinical and pathophysiological insights
Muradashvili T, Liu Y, VanOudenhove J, Gu S, Krause D, Montanari F, Carlino M, Mancuso R, Stempel J, Halene S, Zeidan A, Podoltsev N, Neparidze N. Aplastic anemia in association with multiple myeloma: clinical and pathophysiological insights. Leukemia & Lymphoma 2024, 65: 2182-2189. PMID: 39225418, DOI: 10.1080/10428194.2024.2393260.Peer-Reviewed Original ResearchAplastic anemiaMultiple myelomaImmunosuppressive therapyTransfusion requirementsProgenitor cellsPlasma cell-directed therapyT-cell destructionCell-directed therapiesInhibition of erythroid colony formationErythroid colony formationLevels of IL8Severe AAImmune cytopeniasPartial responseMM patientsHematopoietic stemSerum testsPartial improvementPathophysiological insightsPatientsImmune systemPlatelet apoptosisCytopeniasColony formationMyeloma
2020
Mast cell activation in the systemic sclerosis esophagus
Tom K, Mehta BK, Hoffmann A, Aren K, Carns M, Lee J, Martyanov V, Popovich D, Kosarek N, Wood T, Brenner D, Carlson DA, Ostilla L, Willcocks E, Bryce P, Wechsler JB, Whitfield ML, Hinchcliff M. Mast cell activation in the systemic sclerosis esophagus. Journal Of Scleroderma And Related Disorders 2020, 6: 77-86. PMID: 34179507, PMCID: PMC8225255, DOI: 10.1177/2397198320941322.Peer-Reviewed Original ResearchMast cell numbersSSc patientsCell-directed therapiesSystemic sclerosisEsophageal biopsiesClinical parametersHealthy participantsCell numberNormal-like subsetsMast cell densityCell-targeted therapiesMast cell markersUseful therapeutic approachMast cell activationMast cell quantityRelevant clinical parametersMolecular classification systemEoE patientsEsophageal symptomsEosinophilic esophagitisUpper esophagusSkin biopsiesEntire esophagusMast cellsTherapeutic approaches
2013
Combination Treatment With Anti-CD20 and Oral Anti-CD3 Prevents and Reverses Autoimmune Diabetes
Hu C, Ding H, Zhang X, Wong FS, Wen L. Combination Treatment With Anti-CD20 and Oral Anti-CD3 Prevents and Reverses Autoimmune Diabetes. Diabetes 2013, 62: 2849-2858. PMID: 23447122, PMCID: PMC3717853, DOI: 10.2337/db12-1175.Peer-Reviewed Original ResearchConceptsT cellsNOD miceB cellsT cell-mediated autoimmune diseaseB cell-directed therapiesB cell depletion therapyCell-mediated autoimmune diseaseDiabetic NOD miceTransgenic NOD miceRegulatory T cellsCD4 T cellsCell-directed therapiesAnti-CD3 treatmentType 1 diabetesCD20 monotherapyImportant preclinical evidenceDepletion therapyT1D developmentDendritic cellsIL-10Preclinical evidenceFurther mechanistic studiesAutoimmune diseasesAnti-CD20Suppressive function
2009
Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases
Hu C, Wong F, Wen L. Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases. Clinical & Experimental Immunology 2009, 157: 181-190. PMID: 19604257, PMCID: PMC2730843, DOI: 10.1111/j.1365-2249.2009.03977.x.Peer-Reviewed Original ResearchConceptsB cell-directed therapiesCell-directed therapiesAutoimmune diseasesB cellsT cellsRegulatory B cell subsetsOrgan-specific autoimmune diseasesTranslational Mini‐Review SeriesAmeliorate autoimmune diseaseRegulatory B cellsAnti-inflammatory cytokinesB cell subsetsAutoreactive B cellsMini‐Review SeriesProinflammatory cytokinesSpecific autoantigensCell subsetsTherapyDiseaseVicious cycleCytokinesCellsAutoantibodiesAutoantigensPathogenesis
2008
Editing Antigen Presentation: Antigen Transfer between Human B Lymphocytes and Macrophages Mediated by Class A Scavenger Receptors
Harvey BP, Quan TE, Rudenga BJ, Roman RM, Craft J, Mamula MJ. Editing Antigen Presentation: Antigen Transfer between Human B Lymphocytes and Macrophages Mediated by Class A Scavenger Receptors. The Journal Of Immunology 2008, 181: 4043-4051. PMID: 18768860, PMCID: PMC2701691, DOI: 10.4049/jimmunol.181.6.4043.Peer-Reviewed Original ResearchConceptsHuman B lymphocytesB lymphocytesImmune responseB cellsB cell-directed therapiesChronic autoimmune responseCell-directed therapiesScavenger receptor ASpecific B cellsClass A Scavenger ReceptorB cell APCDendritic cellsAntigen transferAutoimmune responseProfessional APCsEfficient APCsAntigen presentationTransfer of AgSpecific AgReceptor AScavenger receptorsMacrophagesLymphocytesAPCReceptors
2005
Pulmonary Hypertension in Children with Sickle Cell Disease: Clinical Characteristics and Co-Morbidities.
Ambrusko S, Gunawardena S, Sakara A, Windsor B, Lanford L, Michelson P, Krishnamurti L. Pulmonary Hypertension in Children with Sickle Cell Disease: Clinical Characteristics and Co-Morbidities. Blood 2005, 106: 3791. DOI: 10.1182/blood.v106.11.3791.3791.Peer-Reviewed Original ResearchSickle cell diseasePulmonary hypertensionCell diseaseSilent strokeHepatitis CClinical characteristicsAplastic crisisCerebrovascular diseaseTransfusion therapyNocturnal enuresisTR jetTricuspid regurgitant jet velocityChronic transfusion programMoya-Moya syndromeTR jet velocityAcute chest syndromeElevated total bilirubinRestrictive lung diseaseMajority of patientsObstructive sleep apneaRegurgitant jet velocityCell-directed therapiesMiddle cerebral arteryRetrospective case reviewSickle cell patients
2000
T-helper type 2 cell-directed therapy for asthma
Cohn L, Ray A. T-helper type 2 cell-directed therapy for asthma. Pharmacology & Therapeutics 2000, 88: 187-196. PMID: 11150597, DOI: 10.1016/s0163-7258(00)00091-7.BooksConceptsTh2 cell differentiationT helper type 2 cellsNew immunomodulatory strategiesCell-directed therapiesChronic inflammatory diseaseTh2 cell functionType 2 cellsTh cell developmentImmunomodulatory strategiesPathophysiologic abnormalitiesInflammatory diseasesRespiratory tractTh2 cellsImmune responseTraditional therapiesCell differentiationBronchial airwaysAsthmaTherapyCell functionCell effectsCytokinesDiseaseCell developmentMolecular mechanisms
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply